Second Biologic Might Improve Tolerability of Multi-Food Allergy Immunotherapy

(MedPage Today) — PHILADELPHIA — For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ongoing mOIT, although perhaps…